tbuckley/cabot-search huggingface dataset:
Possibilities of minimal invasive technologies combined with target therapy management of hepatic metastases of colorectal cancer.
Authors: Yuri Gevorkyan, Oleg Ivanovich Kit, Natalya Soldatkina, Vladimir Kolesnikov, Dmitry Haragezov, Andrey Dashkov
Journal: Journal of Clinical Oncology (2014)

e14620 Background: To improve results of treatment of hepatic metastases from colorectal cancer by use of laparoscopic surgery in the combined treatment. Methods: Results of treatment of 110 patients with hepatic metastases (up to 5) from colorectal adenocarcinoma T2-3N0-1M1 were analyzed. Main group consist of 50 patients who underwent laparoscopic resection of the colon with liver resection (34 patients) or radiofrequency thermal ablation of metastases (16 patients). Liver intervention was supplemented infiltration of the resected metastasis bed or introduction of 5-FU into zone of necrosis after thermal ablation at a dose of 500 mg per metastasis. Patients also underwent laparoscopic umbilical vein catheterization. The control group consist of 60 patients who underwent laparotomy, resection of the colon with liver resection (48 patients) or radiofrequency thermal ablation of liver metastases (12 patients). Multiple course of polychemotherapy using FOLFOX scheme with panitumumab was performed 2 weeks after surgery: in main group – regionally through the umbilical vein, and in the control group - systemically through a peripheral vein. Results: Postoperative complications occurred in 5% patients of the main group and 12% in the control group. Quality of life score changed in both groups of patients from
Family caregivers' attitude toward inpatients hospice enrollment: An exploratory study.
Authors: Romeo Bascioni, Barbara Esperide, Silvia Miandro, Jacopo Bregoli, Calogero Gucciardino, Maria Rosaria Borriello, Farnoosh Basirat, Francesca Rastelli, Lucio Giustini, Francesca Giorgi
Journal: Journal of Clinical Oncology (2014)

e20507 Background: Hospice care is an underused high-quality end-of-life model of patient care. Family members of patients (pts) are often reluctant to accept inpatient hospice services and efforts are needed to identify barriers to hospice enrollment: a common concern is the risk of physical and emotional detachment from their relative. Methods: Two psychologists conducted a semi-structured telephone interview of family caregivers of cancer pts who had died in our inpatient hospice after a stay of at least 1-week. Questions focused on: (i) level of knowledge about inpatient hospice care; (ii) attitude towards hospice care before and after pts admission; (iii) perception of physical and emotional proximity to their relative; (iv) key quality-of-care issues; and (v) overall satisfaction with the quality of care (measured with a five-point scale: very poor, poor, fair, good, excellent). Results: The leader caregiver of 66 pts was contacted; 63 accepted the interview (40 sons, 8 spouses, 8 in-laws, 3 brother/sister, 4 others). Patients were followed in our inpatient hospice for 1-2 wks (44%), 2-4 wks (46%), > 4 wks (10%). At admission, 35% of caregivers had inadequate knowledge about inpatient hospice care, 36% had been informed by other caregivers who used hospice care in the past, 24% by their oncologist, 5% by the media. Of the caregivers, 11% were initially opposed to the admission, 81% were in favor; 8% had no opinion. All negative opinions were changed to
Severity of pain after unilateral and bilateral primary reconstruction with a tissue expander in breast carcinoma patients.
Authors: Nikola Besic, Branka Strazisar
Journal: Journal of Clinical Oncology (2014)

e20682 Background: After reconstruction, patients have severe post-operative pain, which responds poorly to opioids. Our aim was to compare pain after unilateral and bilateral primary breast reconstruction with a tissue expander. Methods: Unilateral or bilateral immediate reconstruction with a tissue expander was done in 42 and 18 patients, respectively. Half of patients were randomised into local anaesthetic group (0.25% levobupivacaine - flow rate 2 mL/h/expander), and the other half into standard group treated by a continuous intravenous infusion with piritramide. Whenever needed, patients from both groups could get a rescue intravenous bolus of piritramide. Pain was measured using the standard visual analogue scale (VAS) score. Mean VAS score was calculated from 8 and 6 measurements on the day of surgery and on the following days, respectively. Results: Patients had less severe pain after unilateral reconstruction in comparison to bilateral reconstruction during the first three days after surgery (Table). Consumption of piritramide during the first 24 hours after the surgical procedure was lower after unilateral reconstruction compared to bilateral reconstruction (17 vs. 24 mg; p < 0.0001). Consumption of piritramide was lower in the local anaesthetic group compared to the standard group (9.8 vs. 29.4 mg; p < 0.0001). Chronic pain after 3 months was reported after unilateral and bilateral reconstruction in 28% and 44% (p = 0.23), respectively. Conclusions: Pain after bilateral primary reconstruction with a tissue expander is more severe in comparison to unilateral reconstruction. Wound infusion of a local anaesthetic reduces pain. VAS score after reconstruction with unilateral and bilateral tissue expander. Unilateral reconstruction mean (95% CI) Bilateral reconstruction mean (95% CI) P value Recovery room 3.58 (2.86-4.29) 5.50 (4.26-6.73) 0.005 Day of surgery 2.86 (2.63-3.08) 4.42 (3.97-4.87) 0.0001 1st postoperative day 2.63 (2,37-2.88) 3.44 (2.97-3.90) 0.001 2nd postoperative day 2.21 (1.97-2.45) 3.11 (2.67-3.56) 0.0001 3rd postoperative day 1.53 (1.32-1.75) 2.50 (2.12-2.88) 0.001 4th postoperative day 1.71 (1.44-1.98) 1.98 (1.52-2.45) 0.287
Cancer patients (pts) being replaced in dose-seeking phase I trials (DSP1T): Occurrence, outcome, and risk factors.
Authors: Sophie Cousin, Nicolas Isambert, Philippe Alexandre Cassier, Carlos Alberto Gomez-Roca, Nuria Kotecki, Sylvie Zanetta, Juliette Bouchet, Louis Tassy, Anne-Laure Simonet-Lamm, Eleonora De Maio, Catherine Terret, Nicolas Penel
Journal: Journal of Clinical Oncology (2014)

3035 Background: Selection of pts entering in DSPT1 remains challenging. Some predictive scores for early death (within 90 days) or overall survival (OS) have been validated. There is currently no predictive model for identifying pts that will be replaced, whereas this condition interferes with the dose-escalation process and recruitment. Methods: We retrospectively reviewed all consecutive pts enrolled in DSP1T in 4 centers. Royal Marsden Score (RMS) was calculated as follows: 1 point for each of the following parameters: albumin<35 g/l, LDH>ULN and ≥2 metastatic sites (Olmos JCO 2012). Using logistic regression and decision-tree analyses, we have developed a predictive model for excluding pts of high-risk for being replaced. This model maximized the Specificity (Sp) and the Negative predictive value (NPV). Results: Of 332 enrolled pts, 16 pts had to be replaced (4.8%). In all cases, the main reason for early study discontinuation was rapid deterioration of general condition. The median duration of study participation was 18 vs 66 days (p=0.001). The median OS was 45 days vs 480 days (p<0.0001). The 90-day mortality rates were 6/16 (37.5%) vs 19/316 (6.0%). In univariate analysis, the risk factors for being replaced were performance status (PS)=2 (RR=8.2 [2.1-37.4), RMS=3 (RR=35.4 [8.3-150.5]), and enrolment in a study investigating a combination (RR=6.29 [1.98-20.0]). Multivariate analysis had retained PS≥2 and RMS=3 as independent predictive factors for being replaced. We have identified 2 pt subgroups: low-risk of being replaced (RMS≤2 and PS≤1) and high-risk for being replaced (RMS=3 or PS≥2). Rate of being replaced were 8/247 (3.2%) and 8/22 (36.4%) in low and high-risk pts, respectively. Sp and NPV were 94.5% and 94.4%, respectively. Conclusions: About 5% of enrolled pts have to be replaced. These pts experienced very poor outcome. RMS=3 or PS≥2 are predictive for being replaced.
Abstract 14914: Safety and Risk of Diagnostic Cardiac Catheterization
Authors: Mohammed Al-Hijji, Ryan Lennon, Rajiv Gulati, El Sabbagh Abdallah, Jae Yoon Park, Daniel Crusan, Amrit Kanwar, Atta Behfar, Amir Lerman, Gurpeet S Sandhu, David Holmes, Charanjit S Rihal, Singh Mandeep
Journal: Circulation (2017)

Background: Significant procedural improvements have occurred in diagnostic cardiac catheterization over the past 20 years; consequently the risks of major complications following diagnostic cardia...
Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders
Authors: Geoffrey M. Reed, Michael B. First, Cary S. Kogan, Steven E. Hyman, Oye Gureje, Wolfgang Gaebel, Mario Maj, Dan J. Stein, Andreas Maercker, Peter Tyrer, Angelica Claudino, Elena Garralda, Luis Salvador‐Carulla, Rajat Ray, John B. Saunders, Tarun Dua, Vladimir Poznyak, María Elena Medina‐Mora, Kathleen M. Pike, José L. Ayuso‐Mateos, Shigenobu Kanba, Jared W. Keeley, Brigitte Khoury, Valery N. Krasnov, Maya Kulygina, Anne M. Lovell, Jair de Jesus Mari, Toshimasa Maruta, Chihiro Matsumoto, Tahilia J. Rebello, Michael C. Roberts, Rebeca Robles, Pratap Sharan, Min Zhao, Assen Jablensky, Pichet Udomratn, Afarin Rahimi‐Movaghar, Per‐Anders Rydelius, Sabine Bährer‐Kohler, Ann D. Watts, Shekhar Saxena
Journal: World Psychiatry (2019)

Following approval of the ICD‐11 by the World Health Assembly in May 2019, World Health Organization (WHO) member states will transition from the ICD‐10 to the ICD‐11, with reporting of health statistics based on the new system to begin on January 1, 2022. The WHO Department of Mental Health and Substance Abuse will publish Clinical Descriptions and Diagnostic Guidelines (CDDG) for ICD‐11 Mental, Behavioural and Neurodevelopmental Disorders following ICD‐11’s approval. The development of the ICD‐11 CDDG over the past decade, based on the principles of clinical utility and global applicability, has been the most broadly international, multilingual, multidisciplinary and participative revision process ever implemented for a classification of mental disorders. Innovations in the ICD‐11 include the provision of consistent and systematically characterized information, the adoption of a lifespan approach, and culture‐related guidance for each disorder. Dimensional approaches have been incorporated into the classification, particularly for personality disorders and primary psychotic disorders, in ways that are consistent with current evidence, are more compatible with recovery‐based approaches, eliminate artificial comorbidity, and more effectively capture changes over time. Here we describe major changes to the structure of the ICD‐11 classification of mental disorders as compared to the ICD‐10, and the development of two new ICD‐11 chapters relevant to mental health practice. We illustrate a set of new categories that have been added to the ICD‐11 and present the rationale for their inclusion. Finally, we provide a description of the important changes that have been made in each ICD‐11 disorder grouping. This information is intended to be useful for both clinicians and researchers in orienting themselves to the ICD‐11 and in preparing for implementation in their own professional contexts.
Negative Events During Adulthood Are Associated With Symptom Severity and Altered Stress Response in Patients With Irritable Bowel Syndrome
Authors: Colleen H. Parker, Bruce D. Naliboff, Wendy Shih, Angela P. Presson, Elizabeth J. Videlock, Emeran A. Mayer, Lin Chang
Journal: Clinical Gastroenterology and Hepatology (2019)
Impact of the first-line treatment on the clinical course in Japanese NSCLC patients with EGFR mutations.
Authors: Yuichi Sakamori
Journal: Journal of Clinical Oncology (2014)

e19127 Background: It is widely accepted that activating mutation of epidermal growth factor receptor (EGFR) is the most reliable predictive factor for the efficacy of the tyrosine kinase inhibitor of EGFR (EGFR-TKI), such as gefitinib or erlotinib. Therefore, EGFR-TKI is commonly selected for the first-line treatment of metastatic non-small-cell lung cancer (NSCLC) patients with EGFR mutations in clinical practice; however, there is no definite evidence to contradict the use of EGFR-TKI as second-line therapy. Methods: Between August 2004 and December 2013, 146 non-squamous NSCLC patients were proved to be EGFR-positive and received either EGFR-TKI (T) or platinum-based chemotherapy (P) as their first-line treatment at Kyoto University Hospital. We conducted a retrospective analysis of the 146 patients to compare clinical background, survival, and switching rate to second-line treatment between T and P group. Results: Of the 146 patients, 81 received T and 65 received P. The proportion of elderly (p<0.0001), female (p=0.0108), and PS2-4 patients (p<0.0001) were significantly higher in the T group. Fifty-nine patients in the T group and 55 patients in the P group had experienced disease progression at the time of analysis, respectively. In the T group, 40 patients (68%) received chemotherapy as their second-line treatment, including 10 patients (18%) receiving platinum-based chemotherapy; however, the remaining patients (32%) received best supportive care alone. In contrast, 54 patients (98%) of the P group received second-line treatment and all the 54 patients received EGFR-TKI in their clinical course (1 patient; lost to follow-up). Median survival time (MST) was 692 days in the T group and 1043 days in the P group, respectively (p=0.1928). MST was significantly better in patients who received both EGFR-TKI and chemotherapy than those received EGFR-TKI alone (1002 days vs 509 days, p=0.0284); however, the difference disappeared when PS0-1 patients were included (1007 days vs1255 days, p=0.9344). Conclusions: There was no significant difference of overall survival between T and P group though P group included more fragile patients and was less likely to receive second-line treatment.
Efficacy and Toxicity Profile of Ibrutinib Based Regimens for Refractory Multiple Myeloma: A Systematic Review
Authors: Faiza Jamil, Madeeha Shafqat, Ali Younas Khan, Seren Durer, Ceren Durer, Zunairah Shah, Anum Qureshi, Muhammad Abu Zar, Ahmad Kamal, Malik Qistas Ahmad, Chaudhry Saad Sohail, Insija Ilyas Selene, Mustafa Nadeem Malik, Abdul Rafae, Faiz Anwer
Journal: Blood (2018)
Prior Hospitalization Burden and the Relatedness of 30-Day Readmissions in Patients Receiving Hemodialysis
Authors: Eugene Lin, Jay Bhattacharya, Glenn M. Chertow
Journal: Journal of the American Society of Nephrology (2019)

Significance Statement Patients receiving hemodialysis have a high 30-day readmission rate after hospitalization, and Medicare financially penalizes providers with rates that are higher than expected. However, quality measures currently do not account for whether 30-day readmissions are indeed related to the cause for the index hospitalization. This study demonstrates that Medicare patients receiving hemodialysis are significantly more likely to experience an unrelated 30-day readmission if they have a high baseline hospitalization rate, which itself is associated with having more comorbidities and Medicaid status. A related 30-day readmission is most likely to follow cardiac index hospitalizations and least likely to follow renal index hospitalizations. The authors suggest that Medicare consider incorporating prior hospitalization burden and clinical relatedness to improve the clinical meaningfulness of its 30-day readmission quality metrics. Background Thirty-day readmissions are common in patients receiving hemodialysis and costly to Medicare. Because patients on hemodialysis have a high background hospitalization rate, 30-day readmissions might be less likely related to the index hospitalization than in patients with other conditions. Methods In adults with Medicare receiving hemodialysis in the United States, we used multinomial logistic regression to evaluate whether prior hospitalization burden was associated with increased 30-day readmissions unrelated to index hospitalizations with a discharge date from January 1, 2013 to December 31, 2014. We categorized a hospitalization, 30-day readmission pair as “related” if the principal diagnoses came from the same organ system. Results The adjusted probability of unrelated 30-day readmission after any index hospitalization was 19.1% (95% confidence interval [95% CI] 18.9% to 19.3%), 22.6% (95% CI, 22.4% to 22.8%), and 31.2% (95% CI, 30.8% to 31.5%) in patients with 0–1, 2–4, and ≥5 hospitalizations, respectively. Cardiovascular index hospitalizations had the highest adjusted probability of related 30-day readmission: 10.4% (95% CI, 10.2% to 10.7%), 13.6% (95% CI, 13.4% to 13.9%), and 20.8% (95% CI, 20.2% to 21.4%), respectively. Renal index hospitalizations had the lowest adjusted probability of related 30-day readmission: 2.0% (95% CI, 1.8% to 2.3%), 3.9% (95% CI, 3.4% to 4.4%), and 5.1% (95% CI, 4.3% to 5.9%), respectively. Conclusions High prior hospitalization burden increases the likelihood that patients receiving hemodialysis experience a 30-day readmission unrelated to the index hospitalization. Health care payers such as Medicare should consider incorporating clinical relatedness into 30-day readmission quality measures.
Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
Authors: Leo Rasche, Daisy Alapat, Manoj Kumar, Grant Gershner, James E McDonald, Christopher P. Wardell, Samrat Roy Choudhury, Rudy L. Van Hemert, Joshua Epstein, Amy F Williams, Sharmilan Thanendrarajan, Carolina D. Schinke, Michael A Bauer, Cody Ashby, Ruslana G. Tytarenko, Frits van Rhee, Brian A Walker, Maurizio Zangari, Bart Barlogie, Faith E. Davies, Gareth Morgan, Niels Weinhold
Journal: Blood (2018)
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients
Authors: Friederike Christen, Kaja Hoyer, Kenichi Yoshida, Hsin-An Hou, Nils Waldhueter, Michael Heuser, Robert K. Hills, Willy Chan, Raphael Hablesreiter, Olga Blau, Yotaro Ochi, Piroska Klement, Wen-Chien Chou, Igor-Wolfgang Blau, Jih-Luh Tang, Tomasz Zemojtel, Yuichi Shiraishi, Yusuke Shiozawa, Felicitas Thol, Arnold Ganser, Bob Löwenberg, David C. Linch, Lars Bullinger, Peter J. M. Valk, Hwei-Fang Tien, Rosemary E. Gale, Seishi Ogawa, Frederik Damm
Journal: Blood (2019)
rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling
Authors: Francisca Ferrer Marin, Ana Belen F Arroyo, Beatriz Bellosillo, Lurdes Zamora, Ana Kerguelen Fuentes, Patricia Vélez, Elisa Luño, Juan Carlos Hernandez Boluda, Rosa Ayala, Dolly Viviana Fiallo, Jose Valentín García Gutiérrez, Beatriz Arrizabalaga, María Teresa Gómez-Casares, Concepcion Boque, Carmen Garcia-Hernandez, Jesús María Hernández-Rivas, Carles Besses, Vicente Vicente, Alberto Alvarez-Larrán, Raul Teruel Montoya, Rocio González-Conejero, Constantino Martínez
Journal: Blood (2018)
Statin use and risk of liver cancer: A meta-analysis.
Authors: Meng Shi, Xiaobing Cui, Bo Jiang
Journal: Journal of Clinical Oncology (2014)

e15138 Background: Statins are commonly prescribed cholesterol-lowering drugs. Preclinical studies suggest that statins may possess cancer preventive properties. However, the clinical results are inconsistent, as to whether statins can reduce the risk of liver cancer. The primary objective of this meta-analysis was to determine the association between statin use and risk of liver cancer. Methods: A comprehensive literature search of PubMed, BIOSIS Previews, Web of Science, EMBASE, and EBSCO through January 2014 was conducted. The effect estimate was reported as pooled relative risk (RR) with 95% confidence intervals (CIs), using the inverse-variance-weighted random-effects model. The test of heterogeneity, publication bias and subgroup analyses were also performed. Results: A total of 16 (4 RCT, 7 cohort, and 5 case-control) studies were qualified for the meta-analysis, involving 1,784,462 participants with 69,892 liver cancer cases. The results indicated a significant risk reduction of liver cancer among all statin users (RR 0.59, 95% CIs 0.53–0.67). The test of heterogeneity indicated that study design and confounding adjustment but not the location can explain the moderate heterogeneity found in the overall analysis (I2 = 66%). No evidence of public bias was observed. Similar results were also found in the subgroup of lipophilic statin use (RR 0.57, 0.50–0.65, I2 = 40%) and higher cumulative dosage of statin use (> 180 cumulative deﬁned daily dose) (RR 0.54, 0.38-0.77, I2 = 83%). Conclusions: There is a significant inverse association between statin use and risk of liver cancer, when statins are taken daily for cardiovascular event prevention.
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Authors: Pierre-Emmanuel Colombo, Majd Labaki, Caroline Mollevi, Michel Fabbro, Philippe Rouanet
Journal: Journal of Clinical Oncology (2014)

5572 Background: Complete surgery with no macroscopic residual disease at primary or interval debulking surgery (IDS) is the principal goal of the surgical management of advanced epithelial ovarian cancer (EOC). In the case of neoadjuvant chemotherapy (NAC), IDS is generally recommended after 3 to 4 cycles, but few studies have specifically analyzed this point. The aim of this work was to evaluate the impact on survival of the number of NAC cycles before IDS in a large cohort of EOC patients. Methods: Data from patients with advanced EOC (stages IIIC-IV), operated between 1995 and 2010 were consecutively recorded in a prospective database and evaluated retrospectively. Patients treated withNAC/ IDS (group B) were analyzed according to the number of NAC cycles (≤ 4 = group B1; > 4 = group B2) and compared with patients receiving primary surgery (group A). Patients with complete resection were specifically analyzed in both groups. Results: Clinical data of 367 patients with advanced EOC were analyzed. 219 received upfront surgery (group A) and 148 had IDS after NAC (group B). The average follow-up was 82 months. In group B, 38 patients (26%) received more than 4 NAC cycles before IDS (group B2). Patients in group B2 presented more frequently stage IV disease (p=0.015). The rate of complete cytoreduction was higher in group B2 (67%) compared to groups B1 (62%) and A (44%) (p=0.002). Patients in group B2 had worse survival compared to patients in group B1 (p=0.04). Patients with complete surgery at the end of IDS and who had received more than 4 cycles of NAC had poor survival (p<0.001) with a relative risk of death after multivariate analysis of 3 (95% CI : 1.7-5.5]) with an independent impact from stage and performance status. Conclusions: Patients with advanced EOC receiving complete IDS after more than 4 cycles of NAC have poor prognosis. Despite worse prognostic factors observed in this group of patients, our study reinforces the concept of early and complete removal of all macroscopic tumors in the therapeutic sequence of EOC. These results call into question the interest of a delayed debulking in advanced cases thought to be unresectable after 3 to 4 cycles of NAC.
Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study
Authors: Fares Alsawah, Samuel A. Merrill, Paula L. Bockenstedt, Erica L. Campagnaro, Sumana Devata, Scott D. Gitlin, Mark S Kaminski, Alice M. Cusick, Tycel J. Phillips, Suman L. Sood, Moshe Talpaz, Albert Thomas Quiery, Philip S Boonstra, Asra Z. Ahmed, Ryan A. Wilcox
Journal: Blood (2018)